Wall Street brokerages expect that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) will post sales of $10.20 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for BioCryst Pharmaceuticals’ earnings, with the highest sales estimate coming in at $10.82 million and the lowest estimate coming in at $9.58 million. BioCryst Pharmaceuticals reported sales of $9.44 million during the same quarter last year, which indicates a positive year over year growth rate of 8.1%. The business is expected to issue its next quarterly earnings results on Thursday, May 3rd.
According to Zacks, analysts expect that BioCryst Pharmaceuticals will report full year sales of $10.20 million for the current year, with estimates ranging from $6.00 million to $28.61 million. For the next fiscal year, analysts anticipate that the business will report sales of $24.60 million per share, with estimates ranging from $23.02 million to $26.18 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover BioCryst Pharmaceuticals.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.06). BioCryst Pharmaceuticals had a negative net margin of 261.18% and a negative return on equity of 106.53%. The company had revenue of $3.89 million during the quarter, compared to analyst estimates of $6.07 million. During the same quarter last year, the business earned ($0.06) EPS. The company’s revenue for the quarter was down 56.7% compared to the same quarter last year.
A number of brokerages recently weighed in on BCRX. Barclays began coverage on BioCryst Pharmaceuticals in a research note on Wednesday, December 20th. They issued an “equal weight” rating and a $6.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, January 23rd. ValuEngine cut BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 14th. Royal Bank of Canada upgraded BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a research report on Tuesday, January 2nd. Finally, Zacks Investment Research lowered BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, March 5th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals has an average rating of “Hold” and a consensus target price of $8.29.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Los Angeles Capital Management & Equity Research Inc. bought a new position in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $132,000. Trustcore Financial Services LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $126,000. SG Americas Securities LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 98.6% in the 3rd quarter. SG Americas Securities LLC now owns 26,990 shares of the biotechnology company’s stock valued at $141,000 after purchasing an additional 13,402 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $135,000. Finally, Teacher Retirement System of Texas acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $155,000. 91.45% of the stock is owned by institutional investors.
Shares of BioCryst Pharmaceuticals stock traded up $0.02 during trading on Wednesday, hitting $4.62. 616,089 shares of the stock traded hands, compared to its average volume of 1,199,658. The firm has a market cap of $454.03, a price-to-earnings ratio of -5.92 and a beta of 2.71. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.68 and a quick ratio of 1.68. BioCryst Pharmaceuticals has a twelve month low of $3.95 and a twelve month high of $7.45.
COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect BioCryst Pharmaceuticals, Inc. (BCRX) Will Announce Quarterly Sales of $10.20 Million” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another publication, it was stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/09/zacks-brokerages-expect-biocryst-pharmaceuticals-inc-bcrx-will-announce-quarterly-sales-of-10-20-million.html.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.
Get a free copy of the Zacks research report on BioCryst Pharmaceuticals (BCRX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.